BNGO
Bionano Genomics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$1.22
−2.40%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.23
From 52W high−36.79%
Volume132966.00
Market cap$14.37M
P/E (TTM)—
P/S (TTM)0.5x
Div yield—
Key dataOct 19, 2026
Open
$1.23
From 52W high
−36.79%
Volume
132966.00
Market cap
$14.37M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
P/E (TTM)
—
RSI (14)
35.5
MomentumView details →
1D Return
−2.40%
YTD Return
−17.67%
SummaryUpdated Jun 1, 2026
Bionano Genomics, Inc. (NASDAQ:BNGO) is a medical diagnostics and research company founded in 2003 and headquartered in San Diego, California. The company went public in August 2018 and specializes in genome analysis software solutions, particularly through its flagship <b>Optical Genome Mapping (OGM)</b> technology. Originally focused on aggressive growth and customer acquisition, Bionano has undergone significant strategic restructuring since 2024, pivoting from expansion to profitability by dramatically reducing its workforce from over 400 to under 125 employees and focusing on supporting its existing customer base of routine users.
Similar companies
Latest newsMore news →
Bionano Laboratories expanded its optical genome mapping-based diagnostic testing for hematologic malignancies at Memorial Sloan Kettering Cancer Center following approval from the New York State Department of Health.26d agoThree new peer-reviewed studies from independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute demonstrated the clinical value of Bionano's optical genome mapping in myelodysplastic syndromes and acute myeloid leukemia.35d agoBionano Laboratories received approval from the New York State Department of Health for its optical genome mapping-based lab developed tests, enabling clinical use at University of Rochester Medicine.41d ago